Gh Research Plc Quick Ratio (GHRS) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gh Research Plc  (NASDAQ: GHRS)

Gh Research Plc's Quick Ratio

GHRS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Gh Research Plc's Cash & cash equivalent, this led to improvement in Gh Research Plc's Quick Ratio to 65.27, above Gh Research Plc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Quick Ratio than Gh Research Plc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 59.

Explain Quick Ratio?
How much Cash & cash equivalents GHRS´s has?
What are GHRS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GHRS Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -70.28 % -67.75 % -70.09 % -61.83 % 24.56 %
Y / Y Cash & cash equivalent Change 144.32 % 177.21 % 191.37 % 216.14 % 28.53 %
Quick Ratio MRQ 65.27 65.06 73.65 51.31 7.94
GHRS's Total Ranking # 59 # # # #
Seq. Current Liabilities Change -1.67 % 11.31 % -27.8 % -62.39 % 6.68 %
Seq. Cash & cash equivalent Change -1.36 % -1.66 % 3.64 % 143.03 % 11.92 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 13
Overall Market # 59


Quick Ratio Statistics
High Average Low
100.68 37.91 11.26
(Dec 31 2021)   (Dec 31 2024)




Financial Statements
Gh Research Plc's Current Liabilities $ 4 Millions Visit GHRS's Balance sheet
Gh Research Plc's Cash & cash equivalent $ 246 Millions Visit GHRS's Balance sheet
Source of GHRS's Sales Visit GHRS's Sales by Geography


Cumulative Gh Research Plc's Quick Ratio

GHRS's Quick Ratio for the trailling 12 Months

GHRS Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -67.44 % -46.33 % -24.79 % -1.98 % 35.4 %
Y / Y Cash & cash equivalent TTM Growth 179.84 % 154.97 % 109.33 % 54.15 % -3.1 %
Quick Ratio TTM 62.83 34.31 21.02 12.79 7.31
Total Ranking TTM # 2493 # # # #
Seq. Current Liabilities TTM Growth -36.04 % -24.57 % -19.75 % -15.9 % 5.43 %
Seq. Cash & cash equivalent TTM Growth 17.13 % 23.14 % 31.89 % 47.11 % 6.72 %

Quick ratio ranking by company, industry and sector >> Back to GHRS Financial Strength Comparisons >> Go to Compare GHRS Quick Ratio to its Competitors

On the trailing twelve months basis GHRS Cash & cash equivalent more than doubled by 144.32 % in Q4 2025 year on year, while Current Liabilities decreased to $4 millions, this led to increase in in Gh Research Plc's Quick Ratio to 62.83, above GHRS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 395 other companies have achieved higher Quick Ratio than Gh Research Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 2493.

Explain Quick Ratio?
How much Cash & cash equivalents GHRS´s has?
What are GHRS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 396
Healthcare Sector # 760
Within the Market # 2493


trailing twelve months Quick Ratio Statistics
High Average Low
100.68 31.55 11.26
(Dec 31 2021)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Altimmune inc   100.65 $ 273.456  Millions$ 2.717  Millions
Pasithea Therapeutics Corp   97.62 $ 110.419  Millions$ 1.131  Millions
Benitec Biopharma Inc   67.54 $ 97.799  Millions$ 1.448  Millions
Gh Research Plc  65.27 $ 246.251  Millions$ 3.773  Millions
Terns Pharmaceuticals Inc   62.09 $ 1,018.982  Millions$ 16.411  Millions
Spruce Biosciences Inc   51.86 $ 48.906  Millions$ 0.943  Millions
Liquidia Corporation  51.84 $ 190.680  Millions$ 3.678  Millions
Incannex Healthcare Inc  44.54 $ 68.900  Millions$ 1.547  Millions
Emmis Acquisition Corp   43.67 $ 0.948  Millions$ 0.022  Millions
Janux Therapeutics Inc   38.67 $ 966.567  Millions$ 24.997  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Curanex Pharmaceuticals Inc  36.30 $ 4.973  Millions$ 0.137  Millions
Prothena Corporation Public Limited Company  36.01 $ 307.531  Millions$ 8.539  Millions
Minerva Neurosciences Inc   35.93 $ 82.302  Millions$ 2.290  Millions
Ligand Pharmaceuticals Incorporated  33.03 $ 1,236.811  Millions$ 37.447  Millions
Roivant Sciences Ltd   32.71 $ 4,886.891  Millions$ 149.411  Millions
Disc Medicine Inc   32.19 $ 791.152  Millions$ 24.579  Millions
Fulcrum Therapeutics Inc   27.00 $ 352.306  Millions$ 13.048  Millions
Contineum Therapeutics Inc   26.98 $ 262.896  Millions$ 9.744  Millions
Rapport Therapeutics Inc   25.75 $ 490.539  Millions$ 19.049  Millions
Upstream Bio Inc   25.39 $ 341.509  Millions$ 13.452  Millions
Mbx Biosciences Inc   24.12 $ 373.705  Millions$ 15.495  Millions
Structure Therapeutics Inc   22.85 $ 1,446.197  Millions$ 63.285  Millions
Monopar Therapeutics Inc   22.61 $ 61.834  Millions$ 2.735  Millions
Kairos Pharma Ltd   22.57 $ 4.491  Millions$ 0.199  Millions
Sagimet Biosciences inc   22.52 $ 113.124  Millions$ 5.023  Millions
Dyne Therapeutics Inc   21.94 $ 1,110.562  Millions$ 50.625  Millions
Arca Biopharma Inc  21.92 $ 337.044  Millions$ 15.374  Millions
Aprea Therapeutics Inc   20.46 $ 14.599  Millions$ 0.714  Millions
Spyre Therapeutics Inc   20.40 $ 1,197.428  Millions$ 58.685  Millions

Date modified: 2026-08-29T01:27:14+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.